Network analysis of inflammatory mediators in the nasal mucosa and serum showed an anti-inflammatory response (IL-10 upregulation) and T2 inflammatory (CCL11 and CCL24 upregulation) response with co-existent inflammation (upregulation of IL-6 and CXCL8) in early COVID-19 (figure 5A-1). The gene discussed is CCL11; the disease is COVID-19.